What You Should Know:
– A research study by CCS, a leading chronic care management company, reveals that patients receiving continuous glucose monitoring (CGM) devices through medical benefits experience superior adherence and lower costs compared to those accessing them through pharmacy benefits.
– The JMIR Diabetes research — Exploring Real-World Adherence and Cost Implications of Continuous Glucose Monitoring in Patients with Diabetes: Impact of Device Sourcing, highlights the critical role of benefit channel selection in optimizing diabetes management.
Key Findings
- Improved Adherence: Patients obtaining CGMs through the medical benefit demonstrated a 23% higher adherence rate.
- Increased Therapy Reinitiation: Non-adherent patients receiving CGMs through the medical benefit were 22% more likely to resume therapy, compared to only 10% for those on pharmacy benefits.
- Reduced Costs: Adherent patients with CGMs from pharmacy benefits had a 53% higher total cost of care.
The CCS Advantage: Education and Coaching
CCS attributes these positive outcomes to the comprehensive patient education and coaching services offered by medical suppliers providing CGMs. With only half of CGM users reporting access to diabetes self-management education and support, CCS is committed to bridging this gap. Their personalized approach empowers patients to make informed decisions and effectively manage their condition.
Addressing Healthcare Challenges
The study’s findings come at a crucial time, as healthcare staffing shortages and pharmacy closures limit patient access and clinician time for proactive care. CCS’s integrated platform, combining medical devices, pharmaceuticals, and clinical education, addresses these challenges, ensuring a seamless and effective healthcare experience for individuals with chronic conditions.
AI-Powered Predictive Model: PropheSee™
Furthering its commitment to patient support, CCS recently launched PropheSee™, an AI-powered predictive model that identifies patients at risk of treatment non-adherence. By deploying hyper-personalized interventions, PropheSee™ has shown remarkable success in improving patient adherence by up to 50%.
“CGMs are only effective if people use them,” said Dr. Arti Masturzo, Chief Medical Officer at CCS. “This first-of-its-kind research demonstrates that a physician’s decision to direct a patient to use their medical benefit instead of their pharmacy benefit when accessing a medical device can seriously impact health outcomes and costs of care. Data-driven insights like this are highly valuable to clinicians and care teams who are the first line of defense when it comes to improving patient outcomes and reducing waste in our healthcare system.”
